Cargando…

A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma

Karonudib (TH1579) is a novel compound that exerts anti-tumor activities and has recently entered phase I clinical testing. The aim of this study was to conduct a pre-clinical trial in patient-derived xenografts to identify the possible biomarkers of response or resistance that could guide inclusion...

Descripción completa

Detalles Bibliográficos
Autores principales:	Einarsdottir, Berglind O., Karlsson, Joakim, Söderberg, Elin M. V., Lindberg, Mattias F., Funck-Brentano, Elisa, Jespersen, Henrik, Brynjolfsson, Siggeir F., Olofsson Bagge, Roger, Carstam, Louise, Scobie, Martin, Koolmeister, Tobias, Wallner, Olof, Stierner, Ulrika, Berglund, Ulrika Warpman, Ny, Lars, Nilsson, Lisa M., Larsson, Erik, Helleday, Thomas, Nilsson, Jonas A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057880/ https://www.ncbi.nlm.nih.gov/pubmed/30042422 http://dx.doi.org/10.1038/s41419-018-0865-6

Ejemplares similares

Correction: A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma
por: Einarsdottir, Berglind O., et al.
Publicado: (2020)

Karonudib is a promising anticancer therapy in hepatocellular carcinoma
por: Hua, Xiangwei, et al.
Publicado: (2019)

Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts
por: Bhadury, Joydeep, et al.
Publicado: (2016)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Veppil Muralidharan, Somsundar, et al.
Publicado: (2017)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Muralidharan, Somsundar Veppil, et al.
Publicado: (2017)

Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions
por: Einarsdottir, Berglind O., et al.
Publicado: (2014)

Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma
por: Oksvold, Morten P., et al.
Publicado: (2021)

Molecular profiling of driver events in metastatic uveal melanoma
por: Karlsson, Joakim, et al.
Publicado: (2020)

MutT Homolog 1 Inhibitor Karonudib Attenuates Autoimmune Hepatitis by Inhibiting DNA Repair in Activated T Cells
por: Chen, Yong, et al.
Publicado: (2021)

Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study
por: Jespersen, Henrik, et al.
Publicado: (2019)

The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
por: Ny, Lars, et al.
Publicado: (2021)

Mutational Signature and Transcriptomic Classification Analyses as the Decisive Diagnostic Tools for a Cancer of Unknown Primary
por: Bagge, Roger Olofsson, et al.
Publicado: (2018)

Mutations in Cancer Cause Gain of Cysteine, Histidine, and Tryptophan at the Expense of a Net Loss of Arginine on the Proteome Level
por: Tsuber, Viktoriia, et al.
Publicado: (2017)

Crystal structures of NUDT15 variants enabled by a potent inhibitor reveal the structural basis for thiopurine sensitivity
por: Rehling, Daniel, et al.
Publicado: (2021)

Overexpressed c-Myc Sensitizes Cells to TH1579, a Mitotic Arrest and Oxidative DNA Damage Inducer
por: Henriksson, Sofia, et al.
Publicado: (2022)

Broadly Active Antiviral Compounds Disturb Zika Virus Progeny Release Rescuing Virus-Induced Toxicity in Brain Organoids
por: Pettke, Aleksandra, et al.
Publicado: (2020)

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
por: Sanjiv, Kumar, et al.
Publicado: (2015)

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
por: Sanjiv, Kumar, et al.
Publicado: (2016)

Erratum to: Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial
por: Olofsson Bagge, Roger, et al.
Publicado: (2015)

Computational and Experimental Druggability Assessment of Human DNA Glycosylases
por: Michel, Maurice, et al.
Publicado: (2019)

Optimization of N‐Piperidinyl‐Benzimidazolone Derivatives as Potent and Selective Inhibitors of 8‐Oxo‐Guanine DNA Glycosylase 1
por: Wallner, Olov, et al.
Publicado: (2022)

MutT homologue 1 (MTH1) removes N6-methyl-dATP from the dNTP pool
por: Scaletti, Emma Rose, et al.
Publicado: (2020)

Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma
por: Sah, Vasu R., et al.
Publicado: (2021)

Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial
por: Olofsson, Roger, et al.
Publicado: (2014)

Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy
por: Sah, Vasu R., et al.
Publicado: (2023)

In silico Druggability Assessment of the NUDIX Hydrolase Protein Family as a Workflow for Target Prioritization
por: Michel, Maurice, et al.
Publicado: (2020)

Novel Broad-Spectrum Antiviral Inhibitors Targeting Host Factors Essential for Replication of Pathogenic RNA Viruses
por: Tampere, Marianna, et al.
Publicado: (2020)

BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma
por: Funck-Brentano, Elisa, et al.
Publicado: (2020)

NEIL3 Prevents Senescence in Hepatocellular Carcinoma by Repairing Oxidative Lesions at Telomeres during Mitosis
por: Zhao, Zhenjun, et al.
Publicado: (2021)

Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model
por: Jespersen, Henrik, et al.
Publicado: (2017)

The Effect of Beta-Adrenergic Blocking Agents in Cutaneous Melanoma—A Nation-Wide Swedish Population-Based Retrospective Register Study
por: Katsarelias, Dimitrios, et al.
Publicado: (2020)

Reply to Comment on Katsarelias, D., et al. “The Effect of Beta-Adrenergic Blocking Agents in Cutaneous Melanoma—A Nation-Wide Swedish Population-Based Retrospective Register Study.” Cancers 2020, 12, 3228
por: Katsarelias, Dimitrios, et al.
Publicado: (2020)

AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma
por: Das, Ishani, et al.
Publicado: (2020)

MutT homologue 1 (MTH1) catalyzes the hydrolysis of mutagenic O6-methyl-dGTP
por: Jemth, Ann-Sofie, et al.
Publicado: (2018)

Treatment with Anti-HER2 Chimeric Antigen Receptor Tumor-Infiltrating Lymphocytes (CAR-TILs) Is Safe and Associated with Antitumor Efficacy in Mice and Companion Dogs
por: Forsberg, Elin M. V., et al.
Publicado: (2023)

Glioblastoma and glioblastoma stem cells are dependent on functional MTH1
por: Pudelko, Linda, et al.
Publicado: (2017)

Correction: Glioblastoma and glioblastoma stem cells are dependent on functional MTH1
por: Pudelko, Linda, et al.
Publicado: (2020)

MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia
por: Sanjiv, Kumar, et al.
Publicado: (2021)

Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish register-based study
por: Ambring, Anneli, et al.
Publicado: (2012)

Tumor Burden and Health-Related Quality of Life in Patients with Melanoma In-Transit Metastases
por: Wesslau, Hanna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rjehjc6fi9d4pmp1bj4qbugq9n